Is Akebia Therapeutics, Inc. (AKBA) a Buy, Sell, or Hold?
NASDAQ : AKBA
Akebia Therapeutics, Inc.
$1.4 USD
$0.02 (1.45%)
- Volume
- 3.06M
- Average Volume
- 5.12M
- Market Capitalization
- $375.56M
- P/E Ratio
- -18.16
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $4.04
- Year Low
- $0.82
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.40
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | John Butler |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AKBA |
| CUSIP | 00972D105 |
| CIK | 0001517022 |
| Web | https://www.akebia.com |
| Phone | 617 871 2098 |
| Currency | USD |
| Employees | 194 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.46 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.40 |
| Quick Ratio | 1.33 |
| Cash Ratio | 0.94 |
Sales & Book Value
| Annual Sales | $236.2M |
| Price / Sales | 1.62 |
| Cash Flow | 0.22 |
| Price / Cash Flow | 6.26 |
| Price / Book | 13.66 |
Price Target and Rating
| Average Stock Price Forecast | $4.00 |
| High Stock Price Forecast | $4.00 |
| Low Stock Price Forecast | $4.00 |
| Forecast Upside/Downside | -65.00% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.0208 |
| Trailing P/E Ratio | -18.16 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | -$5.34M |
| Net Margin | -8.83% |
| Pretax Margin | -8.07% |
| Return on Equity | -62.72% |
| Return on Assets | -5.66% |
Financials Score
| AltmanZ Score | -5.07 |
| Piotroski Score | 3.00 |
| Working Capital | 69.6M |
| Total Assets | 362.52M |
| Ebit | -7.04M |
| Market Cap | 370.2M |
| Total Liabilities | 335.14M |
Poll Results
About Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical C ... o. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 16:05:00
CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3 newly-hired employees options to purchase an aggregate of 125,600 shares of Akebia's common stock on June 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-06-30 08:00:00
Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO 2 VATE clinical trial program Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's largest privately held and fastest-growing kidney care provider, are pleased to announce today the decision by USRC Kidney Research to stop the Vafseo Outcomes In Center Experience (VOICE) trial following a planned interim analysis.
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
2026-06-10 08:00:00
CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and it has been notified of eligibility to extend the expiration of a composition of matter patent covering Vafseo® (vadadustat).
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
2026-06-04 20:05:13
Akebia Therapeutics NASDAQ: AKBA outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 16:05:00
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia's common stock on May 29, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 08:00:00
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
2026-05-07 15:51:25
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 09:51:03
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Frequently Asked Questions
-
What is the current Akebia Therapeutics, Inc. (AKBA) stock price?
-
Akebia Therapeutics, Inc.(NASDAQ:AKBA) stock price is $1.4 in the last trading session. During the trading session, AKBA stock reached the peak price of $4.04 while $0.823 was the lowest point it dropped to. The percentage change in AKBA stock occurred in the recent session was 1.45% while the dollar amount for the price change in AKBA stock was $0.02.
-
AKBA's industry and sector of operation?
-
The NASDAQ listed AKBA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AKBA?
-
Carolyn Rucci | Senior Vice President, Chief Legal Officer & Secretary
Meredith Bowman | Senior Vice President & Chief People Officer
Erik John Ostrowski | Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer
John Butler | Chief Executive Officer, President & Director
Mercedes Carrasco | Senior Director of Investor & Corporate Communications -
How many employees does AKBA have?
-
Number of AKBA employees currently stands at 194. AKBA operates from 245 First Street, Cambridge, MA 02142, US.
-
Link for AKBA official website?
-
Official Website of AKBA is: https://www.akebia.com
-
How do I contact AKBA?
-
AKBA could be contacted at phone #617 871 2098 and can also be accessed through its website. AKBA operates from 245 First Street, Cambridge, MA 02142, US.
-
How many shares of AKBA are traded daily?
-
The average number of AKBA shares traded daily for last 3 months was 5.12M.
-
What is the market cap of AKBA currently?
-
The market value of AKBA currently stands at $375.56M with its latest stock price at $1.4